Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma.
Boulanger
Emmanuelle
E
Meignin
Véronique
V
Oksenhendler
Eric
E
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D005260:Female; D006566:Herpesviridae Infections / Q000150:complications*; D019288:Herpesvirus 8, Human; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy; D054685:Lymphoma, Primary Effusion / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib